BCL2 and acute myeloid leukemia: Andersen et al. (Andersen et al. 2005) demonstrated that patients with AML had spontaneously arising CTL-reactivity against Bcl-2 in patients but not normal donors, suggesting that vaccines against Bcl-2 could be effective against tumor cells which overexpress this protein.